RELATIONSHIP OF SERUM CREATININE RATIO AND NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME

被引:0
|
作者
Chen, Jian [1 ]
Chen, Yu [2 ]
Tang, Yong [2 ]
Lu, Yingmin [1 ]
Huang, Damin [1 ]
Luo, Xiaohan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, XinHua Chongming Hosp, Dept Cardiol, 25 Nanmengang Rd, Shanghai 202150, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, XinHua Hosp, Dept Cardiol, Shanghai 200092, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2015年 / 31卷 / 05期
关键词
cardiovascular events; chronic renal failure; contrast-induced nephropathy; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; MORTALITY; NEPHROTOXICITY; PREVENTION; OUTCOMES; RISK;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Recent studies suggested that a higher incidence of adverse events was observed in patients with non-ST-segment elevation acute coronary syndrome (ACS) when combined with chronic renal failure (CRF). However, there is no convincing data to show the relationship of serum creatinine and adverse events in those patients. This study aimed to explore the relationship of the serum post-/pre-procedural creatinine ratio in acute coronary syndrome patients with adverse cardiovascular events. Materials and methods: 316 subjects with non-ST-segment elevation acute coronary syndrome were enrolled in the study and underwent percutaneous coronary intervention. Subjects were divided into the normal group (creatinine<97umol/L) and chronic renal failure (CRF) group (creatinine >= 97umol/L) according to the pre-procedure renal function. Serum creatinine ratio (SCrR, post-/pre-procedural) was used to determine the increase of creatinine after PCI (Group 1: SCrR<1.25; Group 2: 1.25 <= SCrR<1.5; Group 3: SCrR >= 1.5). In this study, contrast-induced nephropathy (CIN) was defined as an increased level of serum creatinine by 25% (SCrR >= 1.25) within 72 hours of PCI. In addition, each patient took aspirin and statins according to prescriptions after operation. The use of beta-blockers and angiotensin converting enzyme inhibitors was personally determined. Then, the association between SCrR and adverse cardiovascular events, such as cardiovascular related deaths, recurrent angina pectoris and myocardial infarction were investigated within one-year follow-up. Results: In our study, a higher incidence of CIN and adverse cardiovascular events could be seen in the subjects with chronic renal failure. Besides, the highest ratio of adverse events was found in the group of SCrR >= 1.5. Conclusion: There is a higher ratio of adverse cardiovascular events and contrast-induced nephropathy in subjects with chronic renal failure. In spite of renal function before operation, the incidence of adverse cardiovascular events significantly increased for those with SCrR >= 1.5.
引用
收藏
页码:1051 / 1055
页数:5
相关论文
共 50 条
  • [41] Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes
    Montalescot, Gilles
    Bolognese, Leonardo
    Dudek, Dariusz
    Goldstein, Patrick
    Hamm, Christian
    Tanguay, Jean-Francois
    ten Berg, Jurrien M.
    Miller, Debra L.
    Costigan, Timothy M.
    Goedicke, Jochen
    Silvain, Johanne
    Angioli, Paolo
    Legutko, Jacek
    Niethammer, Margit
    Motovska, Zuzana
    Jakubowski, Joseph A.
    Cayla, Guillaume
    Visconti, Luigi Oltrona
    Vicaut, Eric
    Widimsky, Petr
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11): : 999 - 1010
  • [42] Elevated serum neopterin levels and adverse cardiac events in patients with non-ST-segment elevation acute coronary syndrome
    Kaski, Juan Carlos
    Consuegra-Sanchez, Luciano
    Fernandez-Berges, Daniel J.
    Cruz-Fernandez, Jose M.
    Garcia-Moll, Xavier
    Marrugat, Jaume
    Mostaza, Jose
    CIRCULATION, 2007, 116 (16) : 576 - 576
  • [43] Elevated serum neopterin levels and adverse cardiac events in patients with non-ST-segment elevation acute coronary syndrome
    Carlos, Kaski Juan
    Consuegra, Sanchez Luciano
    Fernandez, Berges Daniel
    Cruz-Fernandez, Jose Maria
    Garcia, Moll Xavier
    Jaume, Marrugat
    Mostaza, Jose
    CARDIOVASCULAR DRUGS AND THERAPY, 2007, 21 : S15 - S15
  • [44] NT-proBNP Levels in Patients with Non-ST-segment Elevation Acute Coronary Syndrome
    Castro, Luiz Ricardo A.
    Alencar, Maria Clara N.
    Barbosa, Marcia M.
    Nunes, Maria do Carmo P.
    Cardoso, Jose Ronaldo
    Ribeiro, Antonio Luiz P.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2011, 97 (06) : 454 - 461
  • [45] Non-ST-segment elevation of acute coronary syndrome. The factors that influence the revascularization strategy
    Malchikova, S. V.
    Kolupaev, A. N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 308 - 309
  • [46] Complete Revascularization in Non-ST-Segment Elevation Acute Coronary Syndrome For Now, Just Do It
    Clemmensen, Peter
    Cavus, Ersin
    Blankenberg, Stefan
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (06) : 783 - 785
  • [47] Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland
    Boeddinghaus, Jasper
    Nestelberger, Thomas
    Kaiser, Christoph
    Twerenbold, Raphael
    Fahrni, Gregor
    Bingisser, Roland
    Khanna, Nina
    Tschudin-Sutter, Sarah
    Widmer, Andreas
    Jeger, Raban
    Kaufmann, Beat
    Pfister, Otmar
    Sticherling, Christian
    Mueller, Christian
    Osswald, Stefan
    Zellweger, Michael J.
    Kuehne, Michael
    IJC HEART & VASCULATURE, 2021, 32
  • [48] Invasive Strategy After Non-ST-Segment Elevation Acute Coronary Syndrome Timing and Controversies
    Jneid, Hani
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (22) : 2277 - 2279
  • [49] The value of clopidogrel administered postoperatively following a non-ST-segment elevation acute coronary syndrome
    Gluckman, TJ
    Rade, JJ
    Schulman, SP
    CHEST, 2005, 127 (06) : 2297 - 2297
  • [50] Underuse of new treatment modalities in diabetics with non-ST-segment elevation acute coronary syndrome
    Vikman, S
    Airaksinen, JEK
    Niemelä, K
    EUROPEAN HEART JOURNAL, 2002, 23 : 585 - 585